Table 8.
Pre- and post-treatment hearing level, overall absolute and relative hearing improvement on the affected ear in subgroups of patients with non-idiopathic sensorineural hearing loss
| Parameter | Pre-treatment | Post-treatment | Absolute hearing gain, ΔPTAabs | Relative hearing gain, ΔPTArel | Relative hearing gain contralateral, ΔPTArelcontral | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean (dBHL) | SD (dBHL) | Mean (dBHL) | Mean (dBHL) | p | Mean (dB) | SD (dB) | p | Mean (%) | SD (%) | p | Mean (%) | SD (%) | p | |
| 10PTA, dBHL | ||||||||||||||
| AOM | 36.9 | 16.5 | 29.9 | 15.0 | < 0.001 | 7.0 | 8.6 | 0.796 | 18.9 | 21.3 | 0.336 | 160.6 | 796.5 | 0.526 |
| VZB | 62.5 | 34.7 | 54.6 | 38.9 | 0.044 | 7.9 | 24.7 | 11.2 | 42.4 | 24.7 | 75.6 | |||
| MD | 32.7 | 9.3 | 27.1 | 14.7 | 0.161 | 5.6 | 10.1 | 21.7 | 35.8 | 40.9 | 64.9 | |||
| O | 52.3 | 32.0 | 65.9 | 42.1 | 0.114 | 3.4 | 15.5 | − 2.3 | 24.5 | 5.7 | 46.1 | |||
| 9PTA, dBHL | ||||||||||||||
| AOM | 37.7 | 16.8 | 30.7 | 15.2 | < 0.001 | 7.0 | 8.7 | 0.783 | 18.5 | 21.3 | 0.292 | 145.8 | 711.3 | 0.565 |
| VZB | 62.7 | 34.4 | 55.1 | 38.7 | 0.056 | 7.7 | 24.8 | 11.2 | 42.1 | 26.9 | 81.8 | |||
| MD | 33.8 | 9.4 | 27.6 | 14.9 | 0.123 | 6.3 | 10.3 | 22.7 | 35.5 | 42.2 | 64.6 | |||
| O | 52.8 | 32.0 | 66.1 | 41.9 | 0.138 | 3.2 | 15.6 | − 2.4 | 24.1 | 5.4 | 48.0 | |||
| 4PTA, dBHL | ||||||||||||||
| AOM | 32.8 | 14.5 | 25.9 | 13.1 | < 0.001 | 6.9 | 8.3 | 0.691 | 20.6 | 22.3 | 0.442 | 50.7 | 80.0 | 0.380 |
| VZB | 62.4 | 36.6 | 54.4 | 40.8 | 0.118 | 8.0 | 26.5 | 6.4 | 62.2 | 10.3 | 137.3 | |||
| MD | 27.5 | 9.5 | 24.4 | 15.8 | 0.483 | 3.1 | 12.7 | 19.0 | 52.8 | 31.6 | 79.0 | |||
| O | 50.6 | 31.2 | 65.0 | 43.3 | 0.073 | 4.5 | 16.2 | 0.5 | 26.8 | 10.4 | 44.4 | |||
| LF-3PTA, dBHL | ||||||||||||||
| AOM | 21.5 | 13.9 | 18.5 | 12.3 | 0.005 | 3.0 | 8.0 | 0.515 | 5.1 | 77.2 | 0.770 | 40.9 | 180.8 | 0.912 |
| VZB | 55.8 | 35.7 | 46.5 | 38.8 | 0.034 | 9.2 | 28.3 | 5.5 | 95.1 | − 39.9 | 424.1 | |||
| MD | 33.5 | 7.9 | 29.8 | 17.4 | 0.484 | 3.8 | 15.4 | 13.4 | 51.3 | 23.0 | 79.0 | |||
| O | 38.9 | 35.5 | 58.1 | 43.5 | 0.020 | 5.3 | 17.3 | − 2.0 | 37.3 | 13.6 | 74.0 | |||
| MF-3PTA, dBHL | ||||||||||||||
| AOM | 43.1 | 17.9 | 33.8 | 17.0 | < 0.001 | 9.3 | 10.6 | 0.28 | 21.5 | 23.8 | 0.284 | 45.4 | 64.0 | 0.301 |
| VZB | 66.3 | 37.8 | 58.1 | 41.1 | 0.189 | 8.2 | 26.2 | 9.8 | 42.9 | − 10.6 | 196.5 | |||
| MD | 25.4 | 15.0 | 20.6 | 12.9 | 0.310 | 4.8 | 11.9 | 23.8 | 42.0 | 49.1 | 82.1 | |||
| O | 60.6 | 32.8 | 69.8 | 44.1 | 0.638 | 3.3 | 19.1 | 0.8 | 30.5 | 12.4 | 48.8 | |||
| HF-2PTA, dBHL | ||||||||||||||
| AOM | 62.3 | 29.8 | 52.2 | 28.9 | < 0.001 | 10.1 | 17.0 | 0.093 | 15.6 | 22.9 | 0.097 | 14.2 | 95.8 | 0.577 |
| VZB | 75.6 | 38.7 | 70.6 | 44.8 | 0.502 | 5.0 | 23.4 | 8.5 | 34.1 | 18.3 | 53.7 | |||
| MD | 41.3 | 18.8 | 32.8 | 16.6 | 0.017 | 8.4 | 9.0 | 22.0 | 21.1 | − 12.6 | 162.9 | |||
| O | 75.4 | 43.1 | 78.6 | 43.8 | 0.602 | 0.6 | 17.6 | − 0.8 | 11.1 | 11.2 | 44.0 | |||
| 3PTAmax, dBHL | ||||||||||||||
| AOM | 59.7 | 24.6 | 49.5 | 23.4 | < 0.001 | 10.2 | 13.3 | 0.671 | 16.9 | 20.6 | 0.324 | |||
| VZM | 80.1 | 34.2 | 69.2 | 37.6 | 0.003 | 10.9 | 23.6 | 13.5 | 31.4 | |||||
| MD | 50.4 | 12.0 | 38.3 | 17.7 | 0.042 | 12.1 | 14.3 | 25.2 | 31.5 | |||||
| O | 74.7 | 40.2 | 76.2 | 37.6 | 0.016 | 5.6 | 15.6 | 2.0 | 13.1 | |||||
AOM Acute otitis media, VZB Varicella zoster/Borrelia, MMenière disease, O Other cause, 10PTA (0.125; 0.25; 0.5; 1; 1.5; 2; 3; 4; 6; 8 kHz), 9PTA (0.125; 0.25; 0.5; 1; 2; 3; 4; 6; 8 kHz), 4PTA: (0.5; 1; 2; 4 kHz), LF3PTA (0.125; 0.5; 1 kHz) MF3PTA (2; 3; 4 kHz), HF2PTA (6; 8 kHz), 3PTAmax (PTA of the three most affected frequencies), ΔPTAabs (Absolute hearing gain), ΔPTArel (Relative hearing gain), ΔPTArelcontral (Relative hearing gain contralateral)